Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

BACKGROUND: Pancreatic adenocarcinoma is a highly lethal malignancy. Neoadjuvant chemo(radio)therapy [NAC(R)T] is recommended to use for borderline resectable pancreatic cancer (BRPC) and high-risk resectable pancreatic cancer (RPC), but no high-level evidence exists. METHODS: We searched PubMed, EM...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Long, Fang, Jing, Tong, Chenhao, Chen, Mingyu, Zhang, Bin, Juengpanich, Sarun, Wang, Yifan, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937851/
https://www.ncbi.nlm.nih.gov/pubmed/31892339
http://dx.doi.org/10.1186/s12957-019-1767-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937851/
https://www.ncbi.nlm.nih.gov/pubmed/31892339
http://dx.doi.org/10.1186/s12957-019-1767-5

Ejemplares similares